

Insurer reported drug pricing data – 2019 report

Top 25 most frequently prescribed drugs – 2019 report

Rank	Drug name	Commonly prescribed for	Manufacturer
1	Hydrocodone-Acetaminophen	Pain Relief	Generic
2	Hydrochlorothiazide	High Blood Pressure	Generic
3	Atorvastatin Calcium	Cholesterol	Generic
4	Ventolin	Asthma	GSK
5	Lisinopril	High Blood Pressure	Generic
6	Amlodipine Besylate	High Blood Pressure	Generic
7	Proair	Asthma	Teva
8	Trazodone Hydrochloride	Depression	Generic
9	Azithromycin	Bacterial Infections	Generic
10	Omeprazole	Acid Reflux	Generic
11	Losartan Potassium	High Blood Pressure	Generic
12	Metformin Hydrochloride	Diabetes	Generic
13	Sertraline Hydrochloride	Depression	Generic
14	Flu Vaccine 2018-2019	Flu Vaccine	Generic
15	Amoxicillin	Bacterial Infections	Generic
16	Levothyroxine Sodium	Thyroid	Generic
17	Gabapentin	Seizures/ Neuralgia	Generic
18	Bupropion Hydrochloride	Depression	Generic
19	Montelukast Sodium	Asthma	Generic
20	Basaglar	Diabetes	Eli Lilly and Company
21	Ondansetron	Nausea/ Vomiting	Generic
22	Escitalopram Oxalate	Depression	Generic
23	Fluoxetine Hydrochloride	Depression	Generic
24	Metoprolol Succinate	High Blood Pressure	Generic
25	Suprep Bowel Prep Kit	Colonoscopy Prep.	Braintree/ Sabela

Common prescription reasons are drawn from the [NIH Drug Information Portal](#) and drug manufacturer websites.

Limitations

The ranks in these combined lists are based only on the rankings in the lists submitted to the Drug Price Transparency Program by the insurance companies based on pharmacy and medical benefits. If a drug is near the top of one of the Top 25 lists, it is near the top of many of the insurance companies' lists as well. The combined lists are not based on any quantitative data such as numbers of enrollees, prescription counts, or dollar amounts.

See Excel file on [insurer webpage](#) for more information and individual lists from each reporting insurer.

A detailed description of the method used to create the combined lists can be found at the end of the [2019 insurer report](#).

Insurer reported drug pricing data – 2019 report

Top 25 most costly drugs – 2019 report

Rank	Drug name	Commonly prescribed for	Manufacturer
1	Humira	Rheumatoid Arthritis/ Crohn's Disease/ Plaque Psoriasis	Abbvie
2	Enbrel	Rheumatoid Arthritis/ Crohn's Disease/ Plaque Psoriasis	Amgen
3	Tecfidera	Relapsing-Remitting Multiple Sclerosis	Biogen
4	Truvada	HIV Treatment	Gilead
5	Stelara	Rheumatoid Arthritis/ Crohn's Disease/ Plaque Psoriasis	Janssen Biotech/ J&J
6	Remicade	Rheumatoid Arthritis/ Crohn's Disease/ Plaque Psoriasis	Janssen Biotech/ J&J
7	Herceptin	Breast Cancer	Genentech/ Roche Holding AG
8	Rituxan	Non-Hodgkin's Lymphoma	Genentech/ Roche Holding AG & Biogen
9	Cosentyx	Plaque Psoriasis	Novartis
10	Genvoya	HIV Treatment	Gilead
11	Tysabri	Relapsing-Remitting Multiple Sclerosis	Biogen
12	Neulasta	Anti-Infective for Chemotherapy	Amgen
13	Revlimid	Multiple Myeloma (Bone Marrow Cancer)	Celgene
14	Copaxone	Relapsing-Remitting Multiple Sclerosis	Teva
15	Soliris	Paroxysmal Nocturnal Hemoglobinuria (Anemia)	Alexion
16	Keytruda	Melanoma/ Other Cancer	Merck
17	Perjeta	Breast Cancer	Genentech/ Roche Holding AG
18	Basaglar	Diabetes	Eli Lilly and Company
19	Odefsey	HIV Treatment	Gilead
20	Ocrevus	Relapsing-Remitting Multiple Sclerosis	Genentech/ Roche Holding AG
21	Triumeq	HIV Treatment	ViiV Healthcare/ GSK/ Pfizer/ Shionogi
22	Epclusa	Hepatitis C	Gilead
23	Opdivo	Melanoma	Bristol-Myers Squibb
24	Humalog	Diabetes	Eli Lilly and Company
25	Novolog	Diabetes	Novo Nordisk

Common prescription reasons are drawn from the [NIH Drug Information Portal](#) and drug manufacturer websites.

Limitations

The ranks in these combined lists are based only on the rankings in the lists submitted to the Drug Price Transparency Program by the insurance companies based on pharmacy and medical benefits. If a drug is near the top of one of the Top 25 lists, it is near the top of many of the insurance companies' lists as well. The combined lists are not based on any quantitative data such as numbers of enrollees, prescription counts, or dollar amounts.

See Excel file on [insurer webpage](#) for more information and individual lists from each reporting insurer.

A detailed description of the method used to create the combined lists can be found at the end of the [2019 insurer report](#).

Insurer reported drug pricing data – 2019 report

Top 25 drugs causing the greatest increase in insurance spending – 2019 report

Rank	Drug name	Commonly prescribed for	Manufacturer
1	Humira	Rheumatoid Arthritis/ Crohn's Disease/ Plaque Psoriasis	Abbvie
2	Mavyret	Hepatitis C	Abbvie
3	Ocrevus	Relapsing-Remitting Multiple Sclerosis	Genentech/ Roche Holding AG
4	Stelara	Rheumatoid Arthritis/ Crohn's Disease/ Plaque Psoriasis	Janssen Biotech/ J&J
5	Truvada	HIV Treatment	Gilead
6	Cosentyx	Plaque Psoriasis	Novartis
7	Revlimid	Multiple Myeloma (Bone Marrow Cancer)	Celgene
8	Herceptin	Breast Cancer	Genentech/ Roche Holding AG
9	Opdivo	Melanoma	Bristol-Myers Squibb
10	Symdeko	Cystic Fibrosis	Vertex
11	Remicade	Rheumatoid Arthritis/ Crohn's Disease/ Plaque Psoriasis	Janssen Biotech/ J&J
12	Enbrel	Rheumatoid Arthritis/ Crohn's Disease/ Plaque Psoriasis	Amgen
13	Neulasta	Anti-Infective for Chemotherapy	Amgen
14	Keytruda	Melanoma/ Other Cancer	Merck
15	Dupixent	Eczema	Regeneron & Genzyme/ Sanofi
16	Basaglar	Diabetes	Eli Lilly and Company
17	Triumeq	HIV Treatment	ViiV Healthcare/ GSK/ Pfizer/ Shionogi
18	Zytiga	Prostate Cancer	Janssen Biotech/ J&J
19	Tagrisso	Non-small-cell Lung Cancer	AstraZeneca
20	Perjeta	Breast Cancer	Genentech/ Roche Holding AG
21	Tecfidera	Relapsing-Remitting Multiple Sclerosis	Biogen
22	Glatiramer Acetate	Relapsing-Remitting Multiple Sclerosis	Generic
23	Rituxan	Non-Hodgkin's Lymphoma	Genentech/ Roche Holding AG & Biogen
24	Eliquis	Stroke Prevention/ Blood Clots	Pfizer & Bristol-Myers Squibb
25	Genvoya	HIV Treatment	Gilead

Common prescription reasons are drawn from the [NIH Drug Information Portal](#) and drug manufacturer websites.

Limitations

The ranks in these combined lists are based only on the rankings in the lists submitted to the Drug Price Transparency Program by the insurance companies based on pharmacy and medical benefits. If a drug is near the top of one of the Top 25 lists, it is near the top of many of the insurance companies' lists as well. The combined lists are not based on any quantitative data such as numbers of enrollees, prescription counts, or dollar amounts.

See Excel file on [insurer webpage](#) for more information and individual lists from each reporting insurer.

A detailed description of the method used to create the combined lists can be found at the end of the [2019 insurer report](#).